Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 23, 2008

Tris Finishes 15,000 Sq. Ft. Expansion

  • Tris Pharma says that its facility expansion in South Brunswick, NJ, is complete. The company reports successful clearance of FDA preapproval inspection.

    The expansion provides approximately 15,000 sq. ft. of additional space to the company's premises and FDA-compliant cGMP facility.

    It allows for additional commercial-scale equipment and a larger warehouse that frees up space for a high-speed packaging area. “FDA's assurance of our facilities and the recent investment in our capabilities means we have ample infrastructure with which to leverage our exciting pipeline of drug delivery technologies and services,” says Ketan Mehta, CEO and founder of Tris Pharma.

    Through its pharma partners, Tris reports that it has more than 30 products in development, submission, or on the market. The firm specializes in controlled-release dosage forms for liquid, solid, and orally disintegrating tablets as well as enhancing bioavailability of poorly absorbed drugs.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »